PsyMuKB

PPI network (data source: BioGrid)

A gene is determined as “expressed” when its expression values are above the pre-determined cutoff, which is the mean normalized expression(base 2 log of (TPM+1)) +1 in all brain tissue from GTEx v7 or BrainSpan data.

A protein is determined as “expressed” when its expression values are above the pre-determined cutoff, which is the normalized expression (base 10 log of iBAQ intensity) ≥0.5 in at least one brain tissue from ProteomicsDB data. Otherwise, a gene or protein is determined as either with below-cutoff expressions or no available data.

	The queried gene/protein
	The interacting partner is expressed at mRNA-level
	The interacting partner is expressed at protein-level
	The interacting partner is expressed at both mRNA and protein level
	The interacting partner is with either below-cutoff expressions or no expression data at both mRNA and protein level
	The interacting partner is hit by coding DNMs
	Physical interaction between queried gene/protein and its partner
	Physical interaction between two interacting partners

Symbol A	GeneA coding DNM count	Symbol B	GeneB coding DNM count	Interaction detection method	Publication	Evidence
TAP2	2	HLA-A	0	affinity chromatography technology	Lewis JW (1996)	1
TAPBP	2	TAP1	0	pull down, affinity chromatography technology, affinity chromatography technology, affinity chromatography technology, affinity chromatography technology, affinity chromatography technology	Raghuraman G (2002), Paulsson KM (2002), Paulsson KM (2002), Park B (2006), Park B (2006), Tan P (2002)	6
HLA-A	0	567	0	affinity chromatography technology, pull down	Lewis JW (1996), Lewis JW (1996)	2
TAP1	0	PDIA3	0	affinity chromatography technology, affinity chromatography technology, affinity chromatography technology, affinity chromatography technology, affinity chromatography technology	Lindquist JA (1998), Park B (2006), Park B (2006), Tan P (2002), Tan P (2002)	5
MOV10	6	COPB1	0	affinity chromatography technology	Castello A (2012)	1
CALR	1	HLA-A	0	unspecified method	Rizvi SM (2004)	1
TAP1	0	HLA-A	0	affinity chromatography technology, affinity chromatography technology, affinity chromatography technology	Paulsson KM (2002), Paulsson KM (2002), Park B (2006)	3
TAP1	0	567	0	affinity chromatography technology, affinity chromatography technology	Park B (2006), Park B (2006)	2
UBC	7	TAPBP	2	pull down	Zhang X (2017)	1
ELAVL1	0	TAPBP	2	affinity chromatography technology	Abdelmohsen K (2009)	1
567	0	TAPBP	2	affinity chromatography technology	Park B (2006)	1
TAP1	0	COPB1	0	affinity chromatography technology	Paulsson KM (2002)	1
ELAVL1	0	CALR	1	affinity chromatography technology	Abdelmohsen K (2009)	1
NXF1	0	COPB1	0	affinity chromatography technology	Castello A (2012)	1
HLA-A	0	COPB1	0	affinity chromatography technology	Paulsson KM (2002)	1
TAPBP	2	HLA-A	0	affinity chromatography technology, affinity chromatography technology	Paulsson KM (2002), Paulsson KM (2002)	2
TAP1	0	CALR	1	affinity chromatography technology, affinity chromatography technology, affinity chromatography technology, affinity chromatography technology	Park B (2006), Park B (2006), Tan P (2002), Tan P (2002)	4
NXF1	0	UBC	7	affinity chromatography technology	Castello A (2012)	1
COPB1	0	COPG1	5	two hybrid, affinity chromatography technology, affinity chromatography technology, pull down, pull down, biochemical, affinity chromatography technology, biochemical, biochemical, biochemical, affinity chromatography technology	Futatsumori M (2000), Lowe M (1996), Futatsumori M (2000), Harter C (1998), Harter C (1998), Pavel J (1998), Wegmann D (2004), Havugimana PC (2012), Kristensen AR (2012), Wan C (2015), Huttlin EL (2017)	11
TAP2	2	567	0	affinity chromatography technology	Lewis JW (1996)	1
PDIA3	0	TAPBP	2	affinity chromatography technology, affinity chromatography technology	Jessop CE (2007), Tan P (2002)	2
CALR	1	567	0	imaging technique	Chen TC (2014)	1
TAPBP	2	COPG1	5	affinity chromatography technology	Paulsson KM (2002)	1
MOV10	6	UBC	7	affinity chromatography technology	Castello A (2012)	1
UBC	7	COPB1	0	affinity chromatography technology, pull down	Matsumoto M (2005), Xu P (2017)	2
TAP1	0	TAP2	2	pull down, affinity chromatography technology, affinity chromatography technology, affinity chromatography technology	Karttunen JT (2001), Park B (2006), Park B (2006), Huttlin EL (2017)	4
TAPBP	2	TAP2	2	pull down	Raghuraman G (2002)	1
TAPBP	2	COPB1	0	affinity chromatography technology	Paulsson KM (2002)	1
HLA-A	0	COPG1	5	affinity chromatography technology	Paulsson KM (2002)	1
NXF1	0	TAPBP	2	affinity chromatography technology	Castello A (2012)	1
MOV10	6	TAPBP	2	affinity chromatography technology	Castello A (2012)	1
UBC	7	HLA-A	0	affinity chromatography technology	Matsumoto M (2005)	1
CALR	1	TAPBP	2	affinity chromatography technology, affinity chromatography technology	Sadasivan B (1996), Tan P (2002)	2
CALR	1	PDIA3	0	affinity chromatography technology, biochemical, pull down, pull down, pull down, biochemical, affinity chromatography technology, affinity chromatography technology	Oliver JD (1999), Oliver JD (1999), Oliver JD (1999), Oliver JD (1999), Leach MR (2002), Wan C (2015), Tan P (2002), Tan P (2002)	8
HTR2C	1	TAPBP	2	affinity chromatography technology	Huttlin EL (2017)	1
TAP1	0	COPG1	5	affinity chromatography technology	Paulsson KM (2002)	1